OBJECTIVES: The aim of this study was to assess the possible protective effect of montelukast against haemorrhagic shock-induced acute lung injury by interfering with inflammatory and oxidative pathways. Acute lung injury following haemorrhagic shock/resuscitation is an important contributor to late morbidity and mortality in trauma patients. Haemorrhagic shock (HS), followed by resuscitation, is considered to be an insult that frequently induces systemic inflammatory response syndrome and oxidative stress, resulting in multiple-organ dysfunction syndrome, including microvascular changes and microscopic damage termed acute lung paraynchymal injury. Montelukast is a cysteinyl leukotriene receptor antagonist that exerts an anti-inflammatory and antioxidant influence.
INTRODUCTION
Haemorrhagic shock (HS) is a commonly encountered complication of blunt trauma or surgical injury. Haemorrhagic shock followed by resuscitation (HSR) is considered to be an insult that frequently induces systemic inflammatory response syndrome (SIRS), resulting in multiple-organ dysfunction syndrome (MODS) including acute lung injury (ALI), which is a major clinical problem, leading to significant mortality and morbidity [1] . The mechanism of pathogenesis of SIRS in the field of HS is complex and a variety of mechanisms are involved. The most widely recognized mechanisms are ischaemia and reperfusion (I/R) and stimulation of cells of the innate immune system [2] . I/R is a major contributor to oxidative stress and SIRS arises during postischaemic resuscitation. I/R injury is, by itself, a potent inflammatory trigger, increasing cytokine release, reactive oxygen species generation, and endothelial activation, with consequent nitric oxide production and expression of adhesion molecules [2] . Neutrophils are the major cellular elements involved in acute lung inflammation after resuscitated haemorrhagic shock [1] . Studies have shown that neutrophils are activated following HS and that lung injury is associated with an increased neutrophil accumulation in the lungs after HS. Following HS, the activated neutrophil appear to infiltrate the injured lung, in parallel with increased expression of adhesion molecules on endothelial cells and elevated local chaemokine/cytokine levels [1] .
As a selective, reversible cysteinyl leukotriene 1 (CysLT1) receptor antagonist, montelukast is used in the treatment of allergic rhinitis and asthma [3] . Montelukast has a gastroprotective effect on indomethacin-induced ulcerations and alendronateinduced lesions of the rat gastric mucosa, which is attributed to its mitigating effect on oxidative damage and myeloperoxidase (MPO) activity [4] . Montelukast ameliorates burn-and sepsisinduced multiorgan damage by a neutrophil-dependent mechanism [5] . Furthermore, montelukast has been shown to reduce I/R-induced oxidative damage in the liver, intestine, kidneys, testes and bladder, because of its anti-inflammatory and antioxidant properties [6] . Also, from our previous work, we found that leukotriene biosynthesis moderates lung injury following haemorrhagic shock [4] . However, to our knowledge, the effect of montelukast on ALI caused by HSR has not been reported.
MATERIALS AND METHODS

Animals and study design
A total of eighteen adult male albino rats weighing 150-220 g were purchased from the Animal Resource Centre at the Institute of Embryo Research and Infertility Treatment of Al-Nahrain University. All experiments were approved by the Animal Care and Research Committee of the University of Kufa, and this investigation conforms to the Guide for the Care and Use of Laboratory Animals (National Research Council, revised 2011). The rats were housed in the animal house of Kufa College of Medicine in a temperature-controlled room (25°C) with alternating 12-h light/ 12-h dark cycles, and were allowed free access to water and chow diet until the start of experiments. After the first week of acclimatization, the rats were randomized into three groups as follows:
Sham group (Group I): this group consisted of six rats, which underwent the same anaesthetic and surgical procedures for an identical period of time as the shocked animals, but neither HS nor fluid resuscitation was performed.
HS group (Group II): this control group consisted of six rats, which underwent HS through a 50% blood loss (30 ml/kg) via intracardiac puncture for 1 h and were then resuscitated with Ringer's lactate (RL) for 1 h and left until the end of the experiment.
Montelukast treated group (Group III): this group consisted of six rats, which received a montelukast 7 mg/kg intraperitoneal injection 30 min before the induction of HS, with the same dose repeated just before the reperfusion period [6] . Montelukast was given before HS as a prophylactic agent in order to reduce subsequent acute lung injury. The drug was purchased from Cayman Chemical Company (Ann Arbor, MI, USA) and prepared immediately before use as a homogenized solution in 2% ethanol. Each dose was homogenized in 1 ml ethanol and injected intraperitoneally [6] . Both sham and HS group rats received the same volume of the ethanol carrier solution.
Haemorrhagic shock protocol
The animals were intraperitoneally anaesthetized with 80 mg/kg ketamine and 8 mg/kg xylazine and subjected to a 50% blood loss (30 ml/kg) via intracardiac puncture from the left side of the chest over 2 min and left in a shock state for 1 h [4] . The animals were then resuscitated with two times blood loss (60 ml/kg) using i.v. lactated Ringers solution via the tail over a period of 1 h [4] . The sham group underwent all the experimental procedures but neither haemorrhage nor resuscitation was carried out. Animals were allowed to breathe spontaneously throughout the experiment. Two hours after the completion of resuscitation, the rats were again anaesthetized and sacrificed by exsanguinations, where the chest cavity was opened and blood samples were taken directly from the heart. The trachea was then isolated and bronchoalveolar lavage was carried out. The lungs were harvested: the left lung was homogenized and stored for use in the study and the right lung was fixed in 10% formalin for histological examination.
Preparation of blood samples and cytokine assays About 3 ml of blood was collected from the heart of each rat. The blood sampling was done at the end of the experiment (2 h after the completion of resuscitation). The blood samples were allowed to clot at 37°C and then centrifuged at 3000 rpm for 15 min; sera were removed and analysed for determination of sera TNF-α and IL-6, which were quantified using enzyme-linked immunosorbent assay (ELISA) kits (Immunotech, France) according to the manufacturer's instructions and guidelines.
Preparation of bronchoalveolar lavage fluid and determination of leukotrienes and total protein
The trachea was then isolated and bronchoalveolar lavage fluid (BALF) was obtained by washing the airways four times with 5 ml of phosphate-buffered saline. The BALF was centrifuged at 1200 × g for 10 min at 4°C. The supernatant was collected and stored at −70°C until analysed for LTB 4 , LTC 4 and total protein [4] . The levels of LTB 4 and LTC 4 in BALF were quantified using ELISA kits (US Biological, Swampscott, USA) according to the manufacturer's instructions and guidelines. Cell-free BALF was evaluated for total protein content using the Biuret method ( photometric/colorimetric test of total proteins) [7] .
Tissue preparation for oxidative stress measurement
The lung specimens were homogenized with a high-intensity ultrasonic liquid processor and sonicated in phosphate-buffered saline containing 0.1 mmol/l EDTA ( pH 7.4) (10%). The homogenate was centrifuged at 10 000 rpm for 15 min at 4°C and the supernatant was used for determination of GSH and MDA [8] . The MDA levels were assayed for products of lipid peroxidation by monitoring thiobarbituric acid-reactive substance formation, according to the method of Buege and Aust in 1978 [9, 10] . Lipid peroxidation was expressed in terms of MDA equivalents using an extinction coefficient of 1.56 × 10 5 M −1 cm −1 and results were expressed as nmol MDA/g tissue. GSH measurements were performed using a colorimetric method at 412 nm (QuantiChrom TM Glutathione Assay Kit, BioAssay Systems, Hayward, CA, USA).
Tissue sampling for histopathology
At the end of the experiment, rats were sacrificed and the lung was harvested. All histopathology specimens were immediately fixed in 10% buffered formalin. After fixation they were processed in the usual manner. The sections were examined by microscope and the histological changes were determined.
The degree of lung injury was assessed using the scoring system described by Matute-Bello et al., which graded congestion of alveolar septae, intra-alveolar cell infiltrates and alveolar haemorrhage [11] . Each parameter was graded on a scale of 0-3, as follows: Alveolar septae, 0: septae thin and delicate; 1: congested alveolar septae in <1/3 of the field; 2: congested alveolar septae in 1/3-2/3 of the field; 3: congested alveolar septae in >2/3 of the field. Intra-alveolar cell infiltrates, 0: <5 intra-alveolar cells per field; 1: 5-10 intra-alveolar cells per field; 2: 10-20 intra-alveolar cells per field; 3: >20 intra-alveolar cells per field. Alveolar haemorrhage, 0: no haemorrhage; 1: at least 5 erythrocytes per alveolus in 1-5 alveoli; 2: at least 5 erythrocytes in 5-10 alveoli; 3: at least 5 erythrocytes in >10 alveoli. The total lung injury score was calculated by adding the individual scores for each category and, according to each sum, lung injury was categorized as normal (0), mild (1-3), moderate (4-6) and severe injury (7) (8) (9) . The histological sections were evaluated by a pathologist without prior knowledge of the treatment given to the animals ( Fig. 1A-D) .
Statistical analysis
Statistical analyses were performed using SPSS 12.0 for Windows. Data were expressed as mean ± SEM. Analysis of variance (ANOVA) was used for the multiple comparisons among all groups, followed by post-hoc tests using Bonferroni correction. The histopathological grading of lung changes is a non-normally distributed variable, measured on an ordinal level of measurement: therefore non-parametric tests were used to assess the statistical significance involving this variable. The statistical significance of difference in total score between more than two groups was assessed by Bonferroni correction. In all tests, P < 0.05 was considered to be statistically significant.
RESULTS
Effect on proinflammatory cytokines (TNF-α and IL-6)
At the end of the experiment, the TNF-α and IL-6 serum levels were significantly higher in the HS group when compared with the sham group (P < 0.05). Treatment with montelukast significantly decreased these levels when compared with the HS group (P < 0.05). The TNF-α and IL-6 values for the different groups are shown in Table 1 .
Effect on lung MDA and GSH levels
The MDA levels, measured as a major degradation product of lipid peroxidation in the pulmonary tissue, were found to be significantly higher in the HS group, as compared to those of the sham group (P < 0.05), while treatment with montelukast abolished these elevations (P < 0.05). The haemorrhagic shock caused a significant decrease in lung GSH level (P < 0.05) when compared with the sham group while, in the montelukast-treated group, the lung GSH level was found to be preserved (P < 0.05) and not significantly different from that of the sham group. The MDA and GSH values for the different groups are shown in Table 2 .
Effect on leukotrienes (LTB 4 and LTC 4 )
At the end of the experiment; the LTB 4 and LTC 4 levels in the BALF were significantly increased in the HS group, as compared with the sham group (P < 0.05). Treatment with montelukast significantly decreased these levels when compared with the HS group (P < 0.05). The LTB 4 and LTC 4 values for the different groups are shown in Table 3 .
Effect on BALF total protein
At the end of the experiment; the total protein level in the BALF was significantly increased in the HS group, as compared with sham group (P < 0.05). Treatment with montelukast significantly decreased the BALF total protein levels when compared with the HS group (P < 0.05). The total protein values for the different groups are shown in Table 4 .
Histological finding
A cross-section of lung from the sham group rats showed the normal appearance of all three parameters (thin and delicate alveolar septae, no intra-alveolar cell infiltrates and no alveolar haemorrhage). All rats in this group showed normal lung appearance (100%) as shown in Tables 5 and 6 .
There was a statistically significant difference between the induced, untreated, HS group and the sham group (P < 0.05) and the total mean score of the HS group showed moderate lung injury. As shown in Tables 5 and 6 and Fig. 1A-D, 66 .7% of the group had moderate lung injury and 33.3% had severe lung injury.
Treatment of rats with montelukast significantly mitigated lung injury (P < 0.05), as compared to the induced, untreated HS group and the total mean score of this group showed mild lung injury. As shown in Table 5 , 16.7% of the group had normal histopathological appearance, 66.6% of the group had mild lung injury and 16.7% of the group had moderate lung injury.
DISCUSSION
The present study demonstrates that HS causes ALI, as evidenced by biochemical and histological changes. Montelukast prevented biochemical changes and protected lung morphology after HS. Although leukotrienes have been known to be associated with I/ R injury in other tissues, including intestine, kidneys, myocardium and liver, there are only a few studies describing the correlation between haemorrhagic shock-induced lung injury and 5-lipoxygenase pathway products. Eun et al. demonstrated in two studies that the 5-lipoxygenase pathway products moderate acute lung injury following haemorrhagic shock [4, [12] [13] [14] .
Jordan et al. demonstrated that LTB 4 levels were significantly increased in rat lungs following T/HS [15] . Studies in humans confirm elevated levels of LTB 4 , LTC 4 , LTD 4 in BALF, pulmonary oedema fluid and plasma in patients with ALI compared with an 'at-risk' group or those with hydrostatic oedema [15] . In the present study, a significant increase in BALF leukotriene (LTB 4 & LTC 4 ) levels were found in the shocked rats, as compared with the sham group. The increased leukotriene level in shocked rats might be due to the associated splanchnic I/R, which activates gut PLA 2 -mediated release of arachidonic acid (AA) into the lymph, whence it is delivered to the lungs [16] . AA is a biologically active lipid, released from the cellular membrane by PLA 2 , which can engage the LTB 4 receptor and initiate LTB 4 production with autocrine effects [4] . AA also promotes 5-lipoxygenase translocation to the nucleus, a key step in leukotrienes production [4] . Additionally, it is known that ischaemia elevates cytosolic calcium concentration, which in turn elevates PLA 2 and lipoxygenase activity, generating leukotrienes. Furthermore, an increased leukotriene level might be due to the leukocytes accumulated in the lungs, as observed in the histological section of the shocked rat lung. Activated neutrophils following haemorrhagic shock are capable of releasing cytotoxic products including leukotrienes, and the intrinsic 5-lipoxygenase activity is required for neutrophil adherence, chaemotaxis and neutrophilmediated lung injury. In addition to neutrophils, alveolar macrophages and circulating macrophages also aggravate lung injury. Alveolar neutrophil sequestration in haemorrhagic shock might contribute to further release of leukotrienes [4] . In this study we have demonstrated that treatment with montelukast appeared to result in significantly lower BALF leukotrienes (LTB 4 and LTC 4 ) levels in the shocked rats, in comparison with the induced, untreated group. In 2006, Sener et al. demonstrated that, in a renal I/R injury model, montelukast significantly decreases the plasma LTB 4 level in rats, as compared with an induced, untreated group [17] . Furthermore, in 2007, Sener et al. demonstrated that, in comparison with an induced, untreated group montelukast significantly decreased the plasma LTB 4 level in rats that underwent chronic renal failure-induced multiple-organ injury [18, 19] . Genovese et al. showed that the spinal cord level of LTB 4 was significantly attenuated in mice treated with montelukast in a model of experimental spinal cord injury [2] .
Haemorrhagic shock is considered to be an insult frequently leading to SIRS including the systemic release of pro-inflammatory cytokines which is central to the inflammatory response. Previous studies have shown that levels of IL-6 and TNF-α significantly increased following trauma-haemorrhage and remain elevated for several hours [4] . The results in the The data expressed as mean ± SEM (n = 6 in each group). *P = 0.04 vs sham group, **P = 0.03 vs HS (induced, untreated) group.
present study are consistent with those reported by Vincenzi et al., who found a significant increase in the TNF-α and IL-6 levels in shocked rats in comparison with a sham group [20, 21] . Activated inflammatory cells, especially macrophages and neutrophils, have been shown to play a pivotal role in the propagation of SIRS following resuscitated shock and could be considered the main source of inflammatory cytokines, including TNF-α and IL-6. In this study montelukast significantly reduced the elevation of IL-6 and TNF-α levels in the shocked rats, as compared with the 'HS' induced, untreated group, suggesting that montelukast has a protective effect in haemorrhagic shockinduced acute lung injury. Sener et al. demonstrated that, in a renal I/R injury model, montelukast significantly decreases the plasma TNF-α and IL-6 level in the ats, as compared with an induced, untreated group [17] . Maeba et al. showed that high doses of montelukast modulate the production of IL-6 and TNF-α through the inhibition of NF-κB activation [22] . The inhibitory action of CysLTs receptor blockers on the generation of pro-inflammatory cytokines was shown in an intestinal I/R injury model, where treatment with CysLTs receptor antagonist markedly suppressed IL-6 levels [22] . Montelukast was found to decrease serum TNF-α level in burn-and sepsis-induced multiple-organ injury in the rats [5] . Furthermore, Kabasakal et al. demonstrated that montelukast significantly decreases the TNF-α serum level in the rats that underwent burn-induced oxidative injury of the gut [23] . Through examination of metabolic processes, GSH has been shown to be important in host defences against oxidative stress. Another important agent showing oxidative stress is MDA, a marker of free radical activity. It was reported that oxidative stress significantly elevated MDA and reduced GSH levels. Oxidative stress has been implicated as an important cause of HSR pathogenesis [4] . The results in our present study are consistent with that reported by Kilicoglu et al., who found a significant increase in lung MDA level and significant decrease in lung GSH level the haemorrhagic shock group, as compared to a sham group in a rat model of haemorrhagic shock-induced acute lung injury [24] . In this study, montelukast significantly reduced the elevation of lung MDA level and significantly elevated the lung GSH level in the shocked rats, as compared with 1.42 ± 0.14** 7.03 ± 0.3**
The data expressed as mean ± SEM (n = 6 in each group). *P = 0.02 vs sham group, **P = 0.03 vs HS (induced, untreated) group. The data expressed as mean ± SEM (n = 6 in each group). *P = 0.03 vs sham group, **P = 0.05 vs HS (induced, untreated) group.
an induced, untreated group, suggesting that montelukast has a protective effect in haemorrhagic shock-induced oxidative injury of the lung. Sener et al. found that montelukast significantly reduced lung MDA level and elevated lung GSH level in the rats that underwent burn-and chronic renal failure-induced oxidative injury of remote organs [17, 19] . Furthermore, montelukast has been shown to reduce I/R-induced oxidative damage in the rat liver, bladder, testes and kidneys through its antiinflammatory and antioxidant properties (by balancing oxidant-antioxidant status) [4] . The antioxidant effect of montelukast was further supported by its action and largely based on its anti-inflammatory effect, where proinflammatory cytokines, chemokines and activated complement factors are responsible for neutrophil recruitment and the subsequent neutrophil-induced oxidant stress during the reperfusion phase [23] . Wang et al. demonstrated that LTC 4 affects the GSH/GSSG (glutathione disulfide) ratio by activating signals to increase IL-8 production, while pretreatment with a leukotriene receptor antagonist, montelukast, significantly suppressed LTC 4 -induced time-dependent changes in the intracellular redox state, and also suppressed upregulation of IL-8 production by suppressing NF-κB activation [25, 26] . On the other hand, CysLTs have been implicated as inflammatory mediators in various studies, based on their potent chaemotactic and chaemokinetic properties (including recruitment of neutrophils), and because of their ability to increase vascular permeability which is a common feature of I/R injury [22] . In the present study, a significant increase in the BALF total protein level was found in the shocked rats, as compared with the sham group, suggesting that haemorrhagic shock induces lung injury in rats. Increased protein concentration in BALF is an important marker of damage to the alveolar-capillary barrier of the lung. Furthermore, the increase in BALF total protein concentration may be due to increased lung permeability and lung oedema during acute lung injury [4] . The acute phase of ALI and ARDS is characterized by the influx of protein-rich oedema fluid into the air spaces as a consequence of increased permeability of the alveolar-capillary barrier [4] . As previously reported, T/HS caused lung injury, as reflected in increased permeability to Evan's Blue dye, BALF protein levels and the BALF-to-plasma protein ratio [4] . Haemorrhagic shock significantly increased BALF total protein in the rats and a similar result has been reported by Eun et al. in mice [14] . CysLTs mediate increased permeability, leading to leukocyte extravasation, plasma exudation and oedema [4] . T/HS lymph induces an increase in endothelial permeability by triggering the release of IL-6 [19] . It has been demonstrated that IL-6 is an important autocrine factor produced by endothelial cells, which contributes to the increase in endothelial permeability during hypoxia. Free radicals are involved in damaging biomembranes, thereby compromising cell integrity and function. Besides increasing pulmonary arterial pressure, free radical production in a hypoxic environment may cause oxidative injury of the endothelium, resulting in increased pulmonary capillary permeability. In this study, treatment with montelukast appeared to have significantly suppressed BALF total protein level in the shocked rats in comparison with the induced, untreated group. Our previous study, and a study by Souza et al., demonstrate that treatment with CysLTs receptor antagonist significantly abolished the increase in vascular permeability in the intestine and lung tissues in an intestinal I/R injury model [4, 27] . The ability of CysLT1 receptor antagonism to reduce plasma protein extravasation in the trachea, bronchi and intra-pulmonary airways of antigen-sensitized rats has been previously reported [4, 18] . Montelukast treatment led to a reduction in haemorrhagic shock-induced increase of protein content in alveoli, suggesting that it moderates the alveolarcapillary barrier damage induced by haemorrhagic shock. In the present study, the antioxidant and anti-inflammatory properties of montelukast may have contributed to its ability to prevent HS-induced increases in lung permeability and pulmonary leukosequestration.
Morphologically, there was a statistically significant difference between the HS group (induced, untreated) and the sham group and the total mean score of the HS group shows moderate lung injury: 66.7% of the HS group had moderate lung injury and 33.3% had severe lung injury. Treatment of rats with montelukast mitigates the lung injury significantly as compared with the HS group and the total mean score of the control group shows mild lung injury. Although there is no data available about the protective effect of montelukast on the lung parenchyma in HS rats, Sener et al. showed that treatment with montelukast ameliorated the degenerated lung epithelium and significantly decreased the number of inflammatory cells in the lungs of rats that underwent chronic renal failure-induced multiple-organ injury [19] . Furthermore, montelukast protects against burn-induced lung injury, as evidenced by amelioration of massive alveolar structural disturbance and disappearance of interstitial haemorrhage [27] . In the context of I/R models, various studies have shown that montelukast can retard histopathological changes in different organs including the liver, kidneys and testes [5] . In the present study, the suppressant effect of montelukast can be attributed to its ability to balance oxidant-antioxidant status and to reduce the generation of pro-inflammatory mediators as well as its inhibitory effect on neutrophil activation and infiltration that have been reported in various studies [5] .
APPENDIX. CONFERENCE DISCUSSION
Dr S. Margaritora (Rome, Italy): You mentioned a plan to treat patients in the future, but what would be the first step towards beginning a clinical study in humans in cases of haemorrhagic shock using montelukast? What would be the first step to begin using it?
Dr Al-Amran: Based on the clinical background, montelukast at least will have no side effects for the patients because it's already prescribed for patients with asthma. What I need to say is that it is a safe drug. So if we want to plan to treat a patient with acute lung injury following severe haemorrhagic shock resuscitation, we can use this drug as a treatment in addition to other treatments planned for such patients with acute lung injury and test for the results, as I said, including lung compliance, pulmonary function tests, chest X-rays, and measurement of the pro-inflammatory cytokines and serum to see how it is going in the human being.
Dr Margaritora: Do you envisage beginning this study with, for example, a patient intubated and on mechanical ventilation?
Dr Al-Amran: Yes, it would be better. Dr Margaritora: And for how many days do you think that you could carry out this kind of treatment?
Dr Al-Amran: In the animal model we just give two doses. It's the same insult. It needs good planning for use in a human being. Until now, we have not started this. Of course, we need a new study, a new protocol, a new proposal.
Dr M. Dusmet (London, United Kingdom): When you look at all of the different mechanisms that lead to acute lung injury or ARDS, you have an insult, whatever it may be. It can be chemical, it can be haemorrhagic shock, it can be any insult, and then fairly rapidly you have a huge surge and release of TNF-alpha, which is a short burst, and that sort of is what gets the whole mechanism of lung injury rolling, and it always rolls in the same manner: you have injury of the endothelium, you then have interstitial problems, and then you have the alveolar wall, the lining cells of the alveolus that are injured, and it's the same pattern, whatever the insult. And the problem we havewhatever the therapeutic mechanism-is that we know that, with most things, you have to deliver your therapy before that surge in TNF-alpha starts, because once you have the surge of TNF-alpha, basically you are predestined to develop acute lung injury or ARDS. So how do you see a mechanism where you can give your agent before the surge in TNF-alpha?
Dr Al-Amran: That's a good question, really. As I said before when I started the talk, haemorrhagic shock resuscitation is a global ischaemia/reperfusion injury. And the main problem here is not with the shock. The main problem is with the reperfusion injury. So the targeting drug, which is the montelukast, will be given before the reperfusion. So this drug will be given before the surge of TNF and other pro-inflammatory cytokines, before the insult happens.
